KZR Kezar Life Sciences
- 0.683
- -0.012-1.69%
- 0.671
- -0.012-1.68%
Kezar Life Sciences News
Express News | Kezar Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Express News | Kezar Life Sciences-Eligible for Additional 180 Calendar Day Period, or Until Nov 25 to Regain Compliance With Nasdaq Minimum Bid Price Requirement
Express News | Kezar Life Sciences Inc -Notified by Nasdaq in Letter Dated May 31, Co’s Application to Transfer to Nasdaq Capital Market Was Approved
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk,
Hold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy Concerns
Express News | Kezar Life Sciences Q1 EPS $(0.30) Beats $(0.33) Estimate
Kezar Life Sciences | 10-Q: Quarterly report
Press Release: Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update -- PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis act
Kezar Life Sciences 1Q Loss/Shr 30c >KZR
Kezar Life Sciences 1Q Loss/Shr 30c >KZR
Express News | Kezar Life Sciences Q1 Operating Expenses USD 23.711 Million
Express News | Kezar Life Sciences Q1 Net Income USD -21.658 Million
Express News | Kezar Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)
Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR
Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR
Express News | Kezar Life Sciences Q4 EPS $(0.44) Misses $(0.38) Estimate
Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR
Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR
Kezar Life Sciences 4Q Loss/Shr 44c >KZR
Kezar Life Sciences 4Q Loss/Shr 44c >KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief
Analysis
Price Target
No Data
